Is Evaxion A/S (EVAX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 37.6% / 30% | 18.8% / 30% | 6.9% / 30% | 7.6% / 5% | ✗ NOT HALAL |
| DJIM | 37.6% / 33% | 18.8% / 33% | 6.9% / 33% | 7.6% / 5% | ✗ NOT HALAL |
| MSCI | 80.9% / 33% | 40.5% / 33% | 14.9% / 33% | 7.6% / 5% | ✗ NOT HALAL |
| S&P | 37.6% / 33% | 18.8% / 33% | 6.9% / 33% | 7.6% / 5% | ✗ NOT HALAL |
| FTSE | 80.9% / 33% | 40.5% / 33% | 14.9% / 50% | 7.6% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -122.7% | |
| Net Margin | -102.4% | |
| Return on Equity (ROE) | -100.2% | |
| Return on Assets (ROA) | -28.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$7M |
| Free Cash Flow | -$7M |
| Total Debt | $8M |
| Debt-to-Equity | 44.0 |
| Current Ratio | 5.8 |
| Total Assets | $28M |
Price & Trading
| Last Close | $3.59 |
| 50-Day MA | $3.59 |
| 200-Day MA | $4.09 |
| Avg Volume | 54K |
| Beta | 0.3 |
|
52-Week Range
$1.20
| |
About Evaxion A/S (EVAX)
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Evaxion A/S (EVAX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Evaxion A/S is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Evaxion A/S's debt ratio?
Evaxion A/S's debt ratio is 37.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 80.9%.
What are Evaxion A/S's key financial metrics?
Evaxion A/S has a market capitalization of $29M, and revenue of $8M. The company maintains a gross margin of 100.0% and a net margin of -102.4%. Return on equity stands at -100.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.